Brian Singerman

Brian Singerman

Brian Singerman, a former partner at Founders Fund and early investor in SpaceX, established his family office to concentrate on high-risk, high-reward technology startups. The wealth originates from his successful venture capital career, including large exits from companies like Stemcentrx, which was acquired by AbbVie for up to $10.2 billion (per Reuters, 2016). The firm invests directly in early-stage companies primarily within North America, with a focus on commercializing breakthrough science. Its portfolio spans AI/ML, digital health, enterprise software, and fintech, with known positions including SpaceX and other space technology ventures. Singerman often leads or co-invests in rounds alongside other institutional venture funds, maintaining a hands-on approach with portfolio companies. The family office operates with a lean team from San Francisco, and Singerman remains active in the venture ecosystem. He has not publicly disclosed total assets under management, but his investing pattern suggests a multi-billion-dollar capacity based on realized and unrealized gains from his Founders Fund era. A recent operational event includes ongoing direct investments in AI and healthcare startups through 2025 and 2026, as tracked by public filings. A structural differentiator is Singerman's ability to source proprietary deals through his extensive network from Founders Fund, where he co-invested alongside Peter Thiel. His background as a PhD candidate in computational biology at Stanford informs a thesis that leverages deep technical diligence in healthcare and science-driven startups, setting him apart from generalist family offices.